Ustekinumab as Induction and Maintenance Therapy for Ulcerative ColitisBruce E. Sands, Colleen Marano, William J. Sandborn et al.|New England Journal of Medicine|2019Cited by 1.2k
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 StudyBruce E. Sands, Zijiang Yang, Kirk Bertelsen et al.|Journal of Crohn s and Colitis|2018Cited by 115
OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFIWilliam J. Sandborn, Colleen Marano, B E Sands et al.|Journal of Crohn s and Colitis|2019Cited by 15
833a – Efficacy in Biologic-Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderatesevere Ulcerative Colitis: UnifiBruce E. Sands, William J. Sandborn, Laurent Peyrin‐Biroulet et al.|Gastroenterology|2019Cited by 3
Tu1739 – Efficacy and Safety of Ustekinumab Through Week 16 in Patients with Moderate to Severe Ulcerative Colitis Randomized to Ustekinumab: Results from the Unifi Induction TrialSilvio Danese, Gert A. Van Assche, Bruce E. Sands et al.|Gastroenterology|2019Cited by 2